Results: 945 news stories
Drug Target Review: Why PARP inhibitors fail: key role of the CST complex in BRCA1-deficient cancers
Drug Target Review: Why PARP inhibitors fail: key role of the CST complex in BRCA1-deficient cancers
Science Magazine: Innovative Urine-Based Tumor DNA Test Promises Personalized Bladder Cancer Therapy
Science Magazine: Innovative Urine-Based Tumor DNA Test Promises Personalized Bladder Cancer Therapy
Medical Xpress: Urine-based tumor DNA test may help personalize bladder cancer treatment
Medical Xpress: Urine-based tumor DNA test may help personalize bladder cancer treatment
MSN.com: Urine-based DNA test predicts bladder cancer recurrence after immunotherapy
MSN.com: Urine-based DNA test predicts bladder cancer recurrence after immunotherapy
Bioengineer.org: Innovative Urine-Based Tumor DNA Test Promises Personalized Bladder Cancer Therapy
Bioengineer.org: Innovative Urine-Based Tumor DNA Test Promises Personalized Bladder Cancer Therapy
News-Medical: Urine-based DNA test predicts bladder cancer recurrence after immunotherapy
News-Medical: Urine-based DNA test predicts bladder cancer recurrence after immunotherapy
WOAI TV (NEWS4SA): UT Health San Antonio receives $3.4M for cancer research and HPV vaccination efforts
WOAI TV (NEWS4SA): UT Health San Antonio receives $3.4M for cancer research and HPV vaccination efforts
New urine-based tumor DNA test may help personalize bladder cancer treatment
In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for recurrence after treatment.
Healthcare IT News: HIMSSCast: How an MD/MS in AI dual degree could change health IT leadership
Healthcare IT News: HIMSSCast: How an MD/MS in AI dual degree could change health IT leadership
PipelineReview.com: Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
PipelineReview.com: Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
FirstWord Pharma: Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
FirstWord Pharma: Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
CancerNetwork: Rhenium Obisbemeda Shows No DLTs and Improves Survival in Recurrent Glioma
CancerNetwork: Rhenium Obisbemeda Shows No DLTs and Improves Survival in Recurrent Glioma
Archynetys.com: BRCA1 & Cancer Resistance — New Study Findings
Archynetys.com: BRCA1 & Cancer Resistance — New Study Findings
Bioengineer.org: UT Health San Antonio Scientists Uncover Key Mechanisms Behind Cancer Drug Resistance
Bioengineer.org: UT Health San Antonio Scientists Uncover Key Mechanisms Behind Cancer Drug Resistance
Science Magazine: UT Health San Antonio Scientists Uncover Key Mechanisms Behind Cancer Drug Resistance
Science Magazine: UT Health San Antonio Scientists Uncover Key Mechanisms Behind Cancer Drug Resistance
Technology Networks: The Role of the CST Complex in Cancer Drug Resistance
Technology Networks: The Role of the CST Complex in Cancer Drug Resistance
Texas Public Radio: A non-opioid painkiller has hit the market, and a San Antonio doctor calls it a game-changer
Texas Public Radio: A non-opioid painkiller has hit the market, and a San Antonio doctor calls it a game-changer
Texas Public Radio (KSTX): San Antonio researcher finds that cholesterol levels may predict Alzheimer’s risk
Texas Public Radio (KSTX): San Antonio researcher finds that cholesterol levels may predict Alzheimer’s risk
Fort Worth Star-Telegram: San Antonio’s newest hospital is first in Texas to offer non-opioid drug
Fort Worth Star-Telegram: San Antonio’s newest hospital is first in Texas to offer non-opioid drug
KSAT 12: UT Health San Antonio hospital first in state to approve new, non-opioid drug for pain
KSAT 12: UT Health San Antonio hospital first in state to approve new, non-opioid drug for pain